Specialized Therapies | HIV and Oncology

Press Releases and Company Announcements

Recent News

btn News

Pipeline & Medicines

Product Pipeline & Portfolio

Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.

btn Pipeline

pipeline Phases

Phase 1
Phase 2
Phase 3

Commercialized Medicine

Our Commercialized Products

btn Medicine

Trogarzo® Logo

Corporate Presentation

Making a difference through innovation

Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.